Project Grant K08CA277014
Award Date 7/5/24
Completion Date 8/31/29
Dollars Obligated $924K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98105, USA
Similar Awards
- This $194,022 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to facilitate the transition of the candidate, an oncologist at the Massachusetts General Hospital (MGH), to independence as a translational oncologist using deep learning (DL) to study therapeutic resistance in solid tumor oncology. The award will support the...
- This federal Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $137,322 to Trustees of Boston University to develop disulfated polyamidosaccharide nanoparticles as a P-selectin targeting chemotherapeutic delivery system. The project aims to investigate the use of these nanoparticles to target and deliver cancer treatments to breast and lung cancer cells, which often exhibit high expression of the P-selectin protein. The award...
- This $128,228 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) is for the development of inhalable extracellular vesicles engineered to deliver interleukin-12 (IL-12) mRNA for lung cancer treatment. The primary goals are to enhance IL-12-based lung cancer immunotherapy by improving exosome-based mRNA delivery, and to investigate the potential role of cardiac fibroblast-derived exosomes in exacerbating lung cancer. The project aims to create more...
- This $400,000 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) aims to develop a novel platform for delivering RNA-based therapeutics to gastrointestinal cancers. The project led by Accure Health Inc. will leverage artificial intelligence to design and engineer specialized membrane vesicles derived from the cyanobacterium Spirulina. These programmable vesicles are intended to enable targeted delivery of RNA-based cancer therapies, such as...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $448,250.00 to The Research Foundation For The State University Of New York (operating as Upstate Medical Center) to develop sulfonium lipid nanoparticles as a novel platform for mRNA delivery. The key objectives of this project are to: 1) expand the chemical diversity of sulfonium lipids by incorporating novel...
- The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $169,884 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate the USP2-POU2F3 signaling pathway as a potential therapeutic target for small cell lung cancer (SCLC). The funded research aims to elucidate the molecular mechanisms regulating the POU2F3 oncoprotein, a key driver of the SCLC-P subtype, with the goal of identifying strategies to degrade POU2F3 and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $635,248 to Trustees of Boston University to develop a novel self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T cell engager (BITE) antibody for the treatment of lung cancer. The key goals are to: Design 5-methylcytidine (5MC) modified SARNA constructs encoding BITE antibodies and evaluate their protein expression performance in vitro. Assess the in vitro and in...
- This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
- The University of California, Davis was awarded a $615,399 project grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) to develop a "transformable nanoparticle (TNP) platform" capable of modulating the tumor microenvironment on-demand using therapeutic peptides and proteins. The goal is to leverage the TNP platform's ability to preferentially accumulate at tumor sites and selectively deliver immunomodulatory payloads to stimulate an anti-tumor...